Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma

NCT06733987 is registered in ClinicalTrials.gov with IRCCS Azienda Ospedaliero-Universitaria di Bologna as lead sponsor.

NCT NCT06733987
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06733987 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
Lead sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Phase
Observational
Overall status
Recruiting
Start date
August 1, 2024
Completion date
February 1, 2027
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma